These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 15334273)
1. Recurrent oedema associated with the co-formulation of lopinavir and ritonavir. Pinto JF; Eyer-Silva WA; Morais-de-Sá CA Rev Soc Bras Med Trop; 2004; 37(4):357-8. PubMed ID: 15334273 [No Abstract] [Full Text] [Related]
2. Hyponatraemia associated with lopinavir--ritonavir? Roberts MT; Aliyu SH Int J Infect Dis; 2007 Jan; 11(1):83-4. PubMed ID: 16574455 [No Abstract] [Full Text] [Related]
3. Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis. Anand H; Parthasarathi G; Ramesh M J Postgrad Med; 2008; 54(2):153-5. PubMed ID: 18480538 [No Abstract] [Full Text] [Related]
4. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor]. Ershov FI; Kas'ianova NV; Vasil'ev AN Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577 [No Abstract] [Full Text] [Related]
5. Focus on hepatitis. Low rate of liver problems seen with LPV/r. Carter M IAPAC Mon; 2005 Oct; 11(10):325. PubMed ID: 16673499 [No Abstract] [Full Text] [Related]
7. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055 [No Abstract] [Full Text] [Related]
8. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Bongiovanni M; Chiesa E; Monforte Ad; Bini T Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401 [No Abstract] [Full Text] [Related]
9. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation. Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839 [TBL] [Abstract][Full Text] [Related]
11. A king in the CASTLE? Optimum initial HIV protease inhibitor. Torti C; Frank I Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849 [No Abstract] [Full Text] [Related]
12. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990 [TBL] [Abstract][Full Text] [Related]